# Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease

> **NCT00010387** · PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 32 (—)

## Conditions studied

- Anemia, Hemolytic, Autoimmune
- Felty Syndrome
- Purpura, Thrombocytopenic
- Autoimmune Diseases

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** filgrastim

## Key facts

- **NCT ID:** NCT00010387
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2007-08
- **Final completion:** —
- **Target enrollment:** 32 (—)
- **Last updated:** 2008-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00010387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00010387, "Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00010387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*